Page 172 - Eceptor News Today

Researchers investigated the potency of trimeric human nephrocystin SH3, TriSb92, a domain-derived antibody, against a conserved region in the receptor-binding domain (RBD) of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

A new study published in the pre-print server medRxiv* hypothesized that the emergence of more immune invasive or transmissible variants of SARS-CoV-2 was associated with increased genetic distinctiveness from the original or previous strains.

Researchers conducted a genomic sequencing and epidemiological correlation analysis of the SARS-CoV-2 Omicron variant.

Researchers determine the serum neutralizing and binding activity against the SARS-CoV-2 Omicron variant in individuals with different levels of immunity.

Researchers recently published a study in the journal Briefings in Bioinformatics wherein they integrated multiple bioinformatics and cheminformatics-based methods to prioritize drugs for the treatment of COVID-19.

New study findings show that the clinical-grade soluble ACE2 effectively inhibits the SARS-CoV-2 Omicron variant, which proves the principle of an effective therapeutic approach against Omicron-driven COVID-19 infections.

A recent study by a team of European researchers demonstrated how antibodies induced by currently circulating influenza A H1N1 strains can cross-react with the important part of the SARS-CoV-2 spike glycoprotein that interacts with the human cell receptor. Their paper is currently available on the medRxiv* preprint server while it undergoes peer review.

Researchers from the University of Colorado Anschutz Medical Campus have been investigating the changes imparted on the Gamma variant by three RBD mutations.

Now in new research, scientists from the University of Leicester have been investigating how these mutations alter the affinities of RBDs to ACE2.